153034-78-7

Basic information

• Product Name: 2-Fluoro-3-iodo-5-methylpyridine
• Synonyms: 2-fluoro-3-iodo-5-methylpyridine;2-FLUORO-3-IODO-5-PICOLINE;2-fluoro-3-iodo-5-fluoropyridine;2-FLUORO-3-IODO-5-PICOLINE (2-FLUORO-3-IODO-5-METHYLPYRIDINE);2,5-difluoro-3-iodopyridine;2-Fluoro-3-iodo-5-picolin
• CAS NO: 153034-78-7
• Molecular Formula: C₆H₅FIN
• Molecular Weight: 237.01
• Product Categories: Pyridine;Halides;Pyridines;Boronic Acid;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Fluorine series
• Mol File: 153034-78-7.mol

Chemical Properties

• Melting Point: 38-42°C
• Boiling Point: 252.471 °C at 760 mmHg
• Flash Point: >110℃
• Appearance: /
• Density: 1.893 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -2.16±0.20(Predicted)
• CAS DataBase Reference: 2-Fluoro-3-iodo-5-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-3-iodo-5-methylpyridine(153034-78-7)
• EPA Substance Registry System: 2-Fluoro-3-iodo-5-methylpyridine(153034-78-7)

Safety Data

• Hazard Codes: T,Xi
• Statements: 36/37/38-36-41-22
• Safety Statements: 26-36-39
• WGK Germany: 3
• Hazardous Substances Data: 153034-78-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoro-3-iodo-5-methylpyridine is used as a key intermediate in the synthesis of protein kinase inhibitors for the treatment of various diseases, including cancer and inflammatory disorders. Its unique structural features allow for the development of targeted therapies that can modulate the activity of specific protein kinases, thereby disrupting disease-causing pathways.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-Fluoro-3-iodo-5-methylpyridine serves as a valuable building block for the design and development of novel therapeutic agents. Its tri-substituted pyridine framework can be further functionalized and modified to create a diverse array of bioactive compounds with potential applications in various therapeutic areas.
Used in Drug Discovery and Development:
2-Fluoro-3-iodo-5-methylpyridine is employed as a starting material in the drug discovery and development process. Its unique chemical properties and reactivity enable the creation of new molecular entities with improved pharmacological profiles, such as enhanced potency, selectivity, and bioavailability. 2-Fluoro-3-iodo-5-methylpyridine plays a crucial role in advancing the development of innovative treatments for a wide range of medical conditions.

Upstream product

• 2369-19-9 2-fluoro-5-methylpyridine 
• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 851607-25-5 2-fluoro-5-methyl-pyridin-3-yllithium 

Downstream Products

• 934542-79-7 4-(2-fluoro-5-methyl-pyridin-3-yl)-3,5-dinitro-benzonitrile 
• 934542-98-0 3-(2-bromo-5-methoxyphenyl)-2-fluoro-5-methyl-pyridine 
• 934542-72-0 3-(6-chloro-3-methyl-2-nitro-4-(trifluoromethyl)phenyl)-2-fluoro-5-methylpyridine 
• 1020203-95-5 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide citrate 
• 1020203-93-3 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide tartrate 
• 1020204-07-2 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide tosylate 
• 1020203-96-6 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide fumarate 
• 1020203-91-1 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide succinate 
• 1020203-86-4 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide benzenesulfate 
• 1020203-99-9 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide phosphate 
• 1020204-01-6 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide benzoate 
• 1020203-97-7 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide sulfate 
• 1020203-88-6 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide methanesulfonate 
• 934543-00-7 5-(4-(2-fluoro-5-methylpyridne-3-yl)-methoxybenzene)-1,3-diamine 

Relevant articles and documents

HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the programmed necrosis pathway.

PYRIDINYLPYRAZOLOQUINOLINE COMPOUND

A compound represented by formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 represents a group represented by the formula: a group represented by the formula: or a group represented by the formula: and R2 represe

Synthesis, radiolabeling and preliminary in vivo evaluation of multimodal radiotracers for PET imaging and targeted radionuclide therapy of pigmented melanoma

Melanin pigment represents an attractive target to address specific treatment to melanoma cells, such as cytotoxic radionuclides. However, less than half of the patients have pigmented metastases. Hence, specific marker is required to stratify this patient population before proceeding with melanin-targeted radionuclide therapy. In such a context, we developed fluorinated analogues of a previously studied melanin-targeting ligand, N-(2-diethylaminoethyl)-6-iodoquinoxaline-2-carboxamide (ICF01012). These latter can be labeled either with 18F or 131I/125I for positron emission tomography imaging (melanin-positive patient selection) and targeted radionuclide therapy purposes. Here we describe the syntheses, radiosyntheses and preclinical evaluations on melanoma-bearing mice model of several iodo- and fluoro(hetero)aromatic derivatives of the ICF01012 scaffold. After preliminary planar gamma scintigraphic and positron emission tomography imaging evaluations, [125I]- and [18F]-N-[2-(diethylamino)ethyl]-4-fluoro-3-iodobenzamides ([125I]4, [18F]4) were found to be chemically and biologically stable with quite similar tumor uptakes at 1 h p.i. (9.7 ± 2.6% ID/g and 6.8 ± 1.9% ID/g, respectively).

PYRAZOLOQUINOLINE DERIVATIVES

A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.

[1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA

The present invention relates to compounds of formula (I) and (IA) useful as inhibitors of protein kinase (1a). The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. (a) : in particular protein kinase C theta, wherein A and A' are independently -N- or -C(R+) -. Ring B is five- or six-membered saturated carbocyclic or heterocyclic R1, R2, R3, R4, R5, R6, R7, x and y are as described herein.

BACTERICIDE COMPOSITION AND METHOD OF CONTROLLING PLANT DISEASE

It is to provide a fungicidal composition having stable and high fungicidal effects against cultivated crops infected with plant diseases resulting from plant diseases. A fungicidal composition containing as active ingredients (a) a benzoylpyridine derivative represented by the formula (I) or its salt: (wherein X is a halogen atom, a nitro group, a substitutable hydrocarbon group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group, a hydroxyl group, a substitutable alkylthio group, a cyano group, a carboxyl group which may be esterified or amidated, or a substitutable amino group, n is 1, 2, 3 or 4; R1 is a substitutable alkyl group, R2' is a substitutable alkyl group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group or a hydroxyl group, p is 1, 2 or 3, and R2" is a substitutable alkoxy group or a hydroxyl group, provided that at least two of R2' and R2" may form a condensed ring containing an oxygen atom) and (b) at least one another fungicide.

3-BENZOYL-2,4,5-SUBSTITUTED PYRIDINE DERIVATIVES OR SALTS THEREOF AND BACTERICIDES CONTAINING THE SAME

To provide 3-benzoyl-2,4,5-substituted pyridine derivatives or their salts, fungicides containing them, and intermediates for producing them. By providing a group of compounds comprising specific 3-benzoyl-2,4,5-substituted pyridine derivatives or their s

Synthesis of 1H-pyridin-2-one derivatives as potent and selective farnesyltransferase inhibitors

The synthesis and biological evaluation of two novel series of potent and selective FTase inhibitors are described. Two novel series of potent and selective FTase inhibitors have been synthesized using structure-based design. Medicinal chemistry efforts led to the discovery of compound 4e with potent cellular activity and good oral bioavailability in dog. A synthetic route toward novel heterocycles 1,5-dimethyl-6-oxo-4-aryl-1,6-dihydro-pyridine-2- carbonitrile was established. The structure of compound 5c was confirmed by X-ray crystallography.

HETEROCYCLIC KINASE INHIBITORS

Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Farnesyltransferase inhibitors

Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.